Lonza’s Mammalian Manufacturing is a leading contract manufacturing provider for biologics. Our offerings include the manufacture of commercial bulk drug substance of monoclonal antibodies (mAbs) and recombinant proteins from mammalian cell cultures. Currently our portfolio includes products that represent essential active pharmaceutical ingredients (APIs) for lifesaving medicines, including cancer treatments and orphan drugs for rare diseases, where no alternative treatment exists.
Today Lonza’s Mammalian Manufacturing has a global commercial manufacturing footprint, comprising production scales from 2,000L to 20,000L across three existing state-of-the-art cGMP manufacturing sites: Portsmouth, NH (USA), Porriño (ES) and Tuas, Singapore (SG). Furthermore, we are adding new capacity in our Ibex® biomanufacturing complex in Visp (CH), with the aim of bringing the right scale of capacity to fulfill different market segments' and customers’ needs.
Our commercial track record and proven expertise over two decades have enabled us to gain a broad accreditation from global health authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). We pride ourselves on being the market leader for highly customized, reliable and innovative solutions to meet customers’ needs.
For further information about our mammalian cell culture capabilities for large-molecule drug substance, as well as for descriptions of Lonza’s mammalian cell-culture facilities, including Portsmouth, Porriño and Singapore, please visit our Mammalian Manufacturing website or explore Lonza’s worldwide sites by location including via our 360° Virtual Tours.